Royal College of Surgeons in Ireland
Browse
Lithium carbonate in amyotrophic lateral sclerosis......pdf (1.23 MB)

Lithium carbonate in amyotrophic lateral sclerosis patients homozygous for the C-allele at SNP rs12608932 in UNC13A: protocol for a confirmatory, randomized, group-sequential, event-driven, double-blind, placebo-controlled trial

Download (1.23 MB)
journal contribution
posted on 2022-12-07, 16:54 authored by Sean W Willemse, Kit C B Roes, Philip Van Damme, Orla Hardiman, Caroline Ingre, Monica Povedano, Naomi R Wray, Marleen Gijzen, Mirjam S de Pagter, Koen C Demaegd, Annemarie F C Janse, Roel G Vink, Boudewijn T H M Sleutjes, Adriano Chiò, Philippe Corcia, Evy Reviers, Ammar Al-Chalabi, Matthew C Kiernan, Leonard H van den Berg, Michael A van Es, Ruben P A van Eijk

Background: Given the large genetic heterogeneity in amyotrophic lateral sclerosis (ALS), it seems likely that genetic subgroups may benefit differently from treatment. An exploratory meta-analysis identified that patients homozygous for the C-allele at SNP rs12608932, a single nucleotide polymorphism in the gene UNC13A, had a statistically significant survival benefit when treated with lithium carbonate. We aim to confirm the efficacy of lithium carbonate on the time to death or respiratory insufficiency in patients with ALS homozygous for the C-allele at SNP rs12608932 in UNC13A.

Methods: A randomized, group-sequential, event-driven, double-blind, placebo-controlled trial will be conducted in 15 sites across Europe and Australia. Patients will be genotyped for UNC13A; those homozygous for the C-allele at SNP rs12608932 will be eligible. Patients must have a diagnosis of ALS according to the revised El Escorial criteria, and a TRICALS risk-profile score between -6.0 and -2.0. An expected number of 1200 patients will be screened in order to enroll a target sample size of 171 patients. Patients will be randomly allocated in a 2:1 ratio to lithium carbonate or matching placebo, and treated for a maximum duration of 24 months. The primary endpoint is the time to death or respiratory insufficiency, whichever occurs first. Key secondary endpoints include functional decline, respiratory function, quality of life, tolerability, and safety. An interim analysis for futility and efficacy will be conducted after the occurrence of 41 events.

Discussion: Lithium carbonate has been proven to be safe and well-tolerated in patients with ALS. Given the favorable safety profile, the potential benefits are considered to outweigh the burden and risks associated with study participation. This study may provide conclusive evidence about the life-prolonging potential of lithium carbonate in a genetic ALS subgroup.

Trial registration: EudraCT number 2020-000579-19 . Registered on 29 March 2021.

Funding

MNDA (UK), Fight MND (Australia) FWO-Vlaan deren (T003519N), ALS Liga (Belgium)

Stichting ALS Nederland (the Netherlands)

Ulla-Carin Lindquist Foundation, (Sweden)

The Thierry Latran Foundation (European Union)

Luzon Fundación (Spain)

My Name’5 Doddie Foundation (UK)

Alan Davidson Foundation (UK)

History

Comments

The original article is available at https://trialsjournal.biomedcentral.com/

Published Citation

Willemse SW. et al. Lithium carbonate in amyotrophic lateral sclerosis patients homozygous for the C-allele at SNP rs12608932 in UNC13A: protocol for a confirmatory, randomized, group-sequential, event-driven, double-blind, placebo-controlled trial. Trials. 2022;23(1):978.

Publication Date

5 December 2022

PubMed ID

36471413

Department/Unit

  • Beaumont Hospital
  • FutureNeuro Centre

Publisher

BioMed Central

Version

  • Published Version (Version of Record)